The cytoplasmic expression of MUC1 in papillary thyroid carcinoma of different histological variants and its correlation with cyclin D1 overexpression

被引:22
作者
Abrosimov, Alexander
Saenko, Vladimir
Meirmanov, Serik
Nakashima, Masahiro
Rogounovitch, Tatiana
Shkurko, Olesya
Lushnikov, Eugeny
Mitsutake, Norisato
Namba, Hiroyuki
Yamashita, Shunichi
机构
[1] Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Dept Int Hlth & Radiat Res, Nagasaki 8528523, Japan
[2] Russian Acad Med Sci, Dept Pathol, Med Radiol Res Ctr, Obninsk 249036, Kaluga, Russia
[3] Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Tissue & Histopathol Sect, Nagasaki 8528523, Japan
[4] Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Dept Mol Med, Nagasaki 8528523, Japan
关键词
papillary thyroid carcinoma; histotype; MUC1; cyclin D1;
D O I
10.1007/s12022-007-0012-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study addressed the immumohistochemical expression of MUC1 in papillary thyroid carcinoma (PTC) of different histotypes, sizes, and morphological features of aggressiveness, and its correlation with the overexpression of cyclin D 1, a target molecule of the Writ pathway. MUC1 expression was examined in a total of 209 PTCs. Cytoplasmic MUCI expression was elevated in the tall, columnar cell and oncocytic variants (100%), Warthin-like (78%), and conventional PTCs (61%), and in papillary microcarcinoma (PMC) with the conventional growth pattern (52%). On the contrary, it was low in the follicular variant (27%) of PTC and PMCs with follicular architecture (13%). Cytoplasmic MUC1 accumulation did not associate with any clinicopathological features except peritumoral lymphoid infiltration in PTCs and in PMCs with the conventional growth pattern. MUC1 staining correlated with cyclin D1 overexpression in conventional PTCs and PMCs and PMCs with follicular architecture. The results demonstrate that MUC1 expression varies broadly in different histological variants of PTC, being the lowest in tumors with follicular structure. In general, it does not prove to be a prognosticator of PTC aggressiveness. A high correlation between MUC1 and cyclin D1 implies MUC1 involvement in the Writ cascade functioning in a large subset of human PTCs and PMCs.
引用
收藏
页码:68 / 75
页数:8
相关论文
共 35 条
[1]   Papillary thyroid carcinoma overexpresses fully and underglycosylated mucins together with native and sialylated simple mucin antigens and histo-blood group antigens [J].
Alves, P ;
Soares, P ;
Fonseca, E ;
Sobrinho-Simoes, M .
ENDOCRINE PATHOLOGY, 1999, 10 (04) :315-324
[2]  
[Anonymous], 2004, World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Endocrine Organs
[3]   PAPILLARY HURTHLE CELL-CARCINOMA WITH LYMPHOCYTIC STROMA - WARTHIN-LIKE TUMOR OF THE THYROID [J].
APEL, RL ;
ASA, SL ;
LIVOLSI, VA .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1995, 19 (07) :810-814
[4]   MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid [J].
Bieche, I ;
Ruffet, E ;
Zweibaum, A ;
Vilde, F ;
Lidereau, R ;
Franc, B .
THYROID, 1997, 7 (05) :725-731
[5]   Wnt signaling: a common theme in animal development [J].
Cadigan, KM ;
Nusse, R .
GENES & DEVELOPMENT, 1997, 11 (24) :3286-3305
[6]   Cell signaling through membrane mucins [J].
Carraway, KL ;
Ramsauer, VP ;
Haq, B ;
Carraway, CAC .
BIOESSAYS, 2003, 25 (01) :66-71
[7]   PAX8-PPARγ rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma [J].
Castro, P ;
Rebocho, AP ;
Soares, RJ ;
Magalhaes, J ;
Roque, L ;
Trovisco, V ;
de Castro, IV ;
Cardoso-de-Oliveira, M ;
Fonseca, E ;
Soares, P ;
Sobrinho-Simoes, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (01) :213-220
[8]   NATURAL-HISTORY, TREATMENT, AND COURSE OF PAPILLARY THYROID-CARCINOMA [J].
DEGROOT, LJ ;
KAPLAN, EL ;
MCCORMICK, M ;
STRAUS, FH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 71 (02) :414-424
[9]  
Fahey T, 2005, SURGERY, V138, P1001
[10]   MUC1, the renaissance molecule [J].
Gendler, SJ .
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2001, 6 (03) :339-353